(Reuters) – An antibody-based COVID-19 therapy developed by GSK and Vir Biotechnology retains neutralising activity against the emerging BA.2 form of the Omicron coronavirus variant, Vir said on Thursday, citing pre-clinical data.
The monoclonal antibody therapy, sotrovimab, is currently authorized for emergency use in the United States. The companies are sharing the latest data with global regulatory authorities, Vir said.
(This story corrects headline and first paragraph to show therapy retains neutralising activity, not that it is effective.)
(Reporting by Sachin Ravikumar in Bengaluru; Editing by Arun Koyyur)
